Ranibizumab biosimilar is under clinical development by Coherus BioSciences and currently in Pre-Registration for Macular Edema. According to GlobalData, Pre-Registration drugs for Macular Edema have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ranibizumab biosimilar overview
Ranibizumab biosimilar (CHS-3351) is under development for the treatment of wet age-related macular degeneration, macular edema secondary to retinal vein occlusion (CRVO and BRVO), diabetic macular edema and diabetic retinopathy. The drug candidate is administered through the intravitreal route. It is a monoclonal antibody fragment (Fab) created from mouse antibody and produced through microbial culture that acts by targeting VEGF-A.
Coherus BioSciences overview
Coherus BioSciences (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate, which is being developed to treat crohn’s disease, ulcerative colitis, and psoriasis arthritis, UDENYCA is a pegfilgrastim biosimilar, CHS-3351 a ranibizumab biosimilar, CHS-2020 a aflibercept biosimilar and CHS-131 a Selective PPAR-gamma modulator. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.